{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:43:45Z","timestamp":1792421025448,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Pathology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.carpath.2020.107202","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T01:58:17Z","timestamp":1579053497000},"page":"107202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5989-0883","authenticated-orcid":false,"given":"Tanner","family":"Hardy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus A.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7450-3300","authenticated-orcid":false,"given":"Iouri","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Nadasdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey V.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carpath.2020.107202_bib1","doi-asserted-by":"crossref","first-page":"102310","DOI":"10.1016\/j.jaut.2019.102310","article-title":"Balancing cancer immunotherapy and immune-related adverse events: the emerging role of regulatory T cells","volume":"104","author":"Alissafi","year":"2019","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.carpath.2020.107202_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918764628","article-title":"Clinical assessment of immune-related adverse events","volume":"10","author":"Sosa","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.carpath.2020.107202_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.carpath.2020.107202_bib4","first-page":"109","article-title":"Clinical response, progression-free survival (pfs) and safety in patients (pts) with advanced melanoma (mel) receiving nivolumab (nivo) combined with ipilimumab (ipi) versus ipi monotherapy in checkmate 069 study","volume":"11","author":"Hodi","year":"2015","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.carpath.2020.107202_bib5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.carpath.2020.107202_bib6","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.carpath.2020.107202_bib7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-Related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.carpath.2020.107202_bib8","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A\u00a0systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.carpath.2020.107202_bib9","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ekir.2019.06.001","article-title":"Anti - PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1","volume":"4","author":"Cassol","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.carpath.2020.107202_bib10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A\u00a0systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.carpath.2020.107202_bib11","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.carpath.2020.107202_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","article-title":"Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab","volume":"9","author":"Tadokoro","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.carpath.2020.107202_bib13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000498985","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.carpath.2020.107202_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.lungcan.2016.06.025","article-title":"Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung","volume":"99","author":"Semper","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.carpath.2020.107202_bib15","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/1556-4029.13633","article-title":"Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab","volume":"63","author":"Matson","year":"2018","journal-title":"J\u00a0Forensic Sci"},{"key":"10.1016\/j.carpath.2020.107202_bib16","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00432-019-02927-x","article-title":"Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases","volume":"145","author":"Atallah-Yunes","year":"2019","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.carpath.2020.107202_bib17","first-page":"812 e1","article-title":"Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab","volume":"34","author":"Yamaguchi","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.carpath.2020.107202_bib18","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.carpath.2020.107202_bib19","series-title":"Handbook of autopsy practice","author":"Ludwig","year":"2002"},{"key":"10.1016\/j.carpath.2020.107202_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jjco\/hyx154","article-title":"Immune checkpoint inhibitor-related myocarditis","volume":"48","author":"Tajiri","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.carpath.2020.107202_bib21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijcard.2019.07.025","article-title":"Diagnosis of immune checkpoint inhibitor-associated myocarditis: a systematic review","volume":"296","author":"Pradhan","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carpath.2020.107202_bib22","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis","volume":"188","author":"Tarrio","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.carpath.2020.107202_bib23","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/ecco-jcc\/jjx081","article-title":"Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities","volume":"11","author":"Coutzac","year":"2017","journal-title":"J\u00a0Crohn's and Colitis"}],"container-title":["Cardiovascular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054880720300065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054880720300065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:45:59Z","timestamp":1760960759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054880720300065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":23,"alternative-id":["S1054880720300065"],"URL":"https:\/\/doi.org\/10.1016\/j.carpath.2020.107202","relation":{},"ISSN":["1054-8807"],"issn-type":[{"value":"1054-8807","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carpath.2020.107202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107202"}}